Short‐Term BMP‐2 Expression Is Sufficient for In Vivo Osteochondral Differentiation of Mesenchymal Stem Cells
- 1 January 2004
- journal article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 22 (1), 74-85
- https://doi.org/10.1634/stemcells.22-1-74
Abstract
Currently available murine models to evaluate mesenchymal stem cell (MSC) differentiation are based on cell injection at ectopic sites such as muscle or skin. Due to the importance of environmental factors on the differentiation capacities of stem cells in vivo, we investigated whether the peculiar synovial/cartilaginous environment may influence the lineage specificity of bone morphogenetic protein (BMP)-2-engineered MSCs. To this aim, we used the C3H10T1/2-derived C9 MSCs that express BMP-2 under control of the doxycycline (Dox)-repressible promoter, Tet-Off, and showed in vitro, using the micropellet culture system that C9 MSCs kept their potential to differentiate toward chondrocytes. Implantation of C9 cells, either into the tibialis anterior muscles or into the joints of CB17-severe combined immunodeficient bg mice led to the formation of cartilage and bone filled with bone marrow as soon as day 10. However, no differentiation was observed after injection of naïve MSCs or C9 cells that were repressed to secrete BMP-2 by Dox addition. The BMP-2-induced differentiation of adult MSCs is thus independent of soluble factors present in the local environment of the synovial/cartilaginous tissues. Importantly, we demonstrated that a short-term expression of the BMP-2 growth factor is necessary and sufficient to irreversibly induce bone formation, suggesting that a stable genetic modification of MSCs is not required for stem cell-based bone/cartilage engineering.Keywords
This publication has 39 references indexed in Scilit:
- Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effectMolecular Therapy, 2003
- Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4Journal of Clinical Investigation, 2002
- Bone Morphogenetic Protein-Transduced Human Fibroblasts Convert to Osteoblasts and Form Bonein VivoTissue Engineering, 2002
- BMP‐2, BMP‐4, and PDGF‐bb stimulate chemotactic migration of primary human mesenchymal progenitor cellsJournal of Cellular Biochemistry, 2002
- Regeneration of Hyaline Cartilage by Cell-Mediated Gene Therapy Using Transforming Growth Factorβ1-Producing FibroblastsHuman Gene Therapy, 2001
- Exogenously Regulated Stem Cell-Mediated Gene Therapy for Bone RegenerationMolecular Therapy, 2001
- Gene Therapy-Directed Osteogenesis: BMP-7-Transduced Human Fibroblasts Form Bonein VivoHuman Gene Therapy, 2000
- Type IIA Procollagen Containing the Cysteine-rich Amino Propeptide Is Deposited in the Extracellular Matrix of Prechondrogenic Tissue and Binds to TGF-β1 and BMP-2The Journal of cell biology, 1999
- Articular Chondrocytes Produce Factors That Inhibit Maturation of Sternal Chondrocytes in Serum-Free Agarose Cultures: A TGF-β Independent ProcessJournal of Bone and Mineral Research, 1997
- Mesenchymal stem cellsJournal of Orthopaedic Research, 1991